Autologous hematopoietic stem cell transplantation (auto-HSCT) in children in Poland: 2021 indications and practice
Abstract
Unlike in adults, the number of pediatric autologous hematopoietic stem cell transplants (HSCT) has decreased in last years. This is because of changing indications for this type of treatment and new therapies available in recent years. Polish pediatric HSCT centers have followed the published recommendations of the Polish Pediatric Hematopoietic Stem Cell Transplantation Group, which are generally based on European Society for Blood and Marrow Transplantation indications. Differences are observed in obtaining autologous hematopoietic stem cells from children compared to adults in terms of the timing of the scheduled harvest and technical aspects of the harvesting procedure. As a result, stem cell harvesting in pediatric populations involves more medical professionals, and requires more time and more financial resources compared to adults. Pediatric autologous stem cell transplantation in neuroblastoma and Ewing’s sarcoma has confirmed efficacy. Autologous cell harvesting in young children established in autologous transplant procedure is now increasingly used in apheresis of lymphocytes for approved CAR-T cell therapies in relapsed/resistant leukemia and lymphoma. Recent studies suggest that cell-based immunotherapy is a potential treatment for refractory or relapsed pediatric solid tumors.
Keywords: autologous stem cell transplantationchildrenstem cell harvest
References
- Passweg JR, Baldomero H, Chabannon C, et al. European Society for Blood and Marrow Transplantation (EBMT). Hematopoietic cell transplantation and cellular therapy survey of the EBMT: monitoring of activities and trends over 30 years. Bone Marrow Transplant. 2021 [Epub ahead of print].
- Wachowiak J, Balwierz W, Chybicka A, et al. Wskazania do transplantacji komórek krwiotwórczych u dzieci i młodzieży – rekomendacje Polskiej Pediatrycznej Grupy ds. Transplantacji Komórek Krwiotwórczych – 2014. Acta Haematol Pol. 2014; 45(4): 301–312.
- EBMT Handbook 2019. https://www.gvhd.eu/wp-content/uploads/2019/03/The-EBMT-Handbook-2019.pdf (May 4, 2021).
- Doberschuetz N, Soerensen J, Bonig H, et al. Mobilized peripheral blood stem cell apheresis via Hickman catheter in pediatric patients. Transfusion. 2019; 59(3): 1061–1068.
- Ohara Y, Ohto H, Tasaki T, et al. Comprehensive technical and patient-care optimization in the management of pediatric apheresis for peripheral blood stem cell harvesting. Transfus Apher Sci. 2016; 55(3): 338–343.
- Ladenstein R, Pötschger U, Hartman O, et al. EBMT Paediatric Working Party. 28 years of high-dose therapy and SCT for neuroblastoma in Europe: lessons from more than 4000 procedures. Bone Marrow Transplant. 2008; 41 Suppl 2: S118–S127.
- Whelan J, Le Deley MC, Dirksen U, et al. Euro-E.W.I.N.G.99 and EWING-2008 Investigators. High-dose chemotherapy and blood autologous stem-cell rescue compared with standard chemotherapy in localized high-risk Ewing sarcoma: results of Euro-E.W.I.N.G.99 and Ewing-2008. J Clin Oncol. 2018 [Epub ahead of print]: JCO2018782516.
- Passweg JR, Baldomero H, Peters C, et al. European Society for Blood and Marrow Transplantation EBMT. Hematopoietic SCT in Europe: data and trends in 2012 with special consideration of pediatric transplantation. Bone Marrow Transplant. 2014; 49(6): 744–750.
- Wachowiak J, Chybicka A, Kowalczyk JR, et al. Development and current use of in hematopoietic stem cell transplantation in children and adolescents in Poland: Report of the Polish pediatric study group for hematopoietic stem cell transplantation of the Polish society for pediatric oncology and hematology. Transfus Apher Sci. 2018; 57(3): 316–322.
- Mora J, Castañeda A, Colombo MC, et al. Clinical and pathological evidence of anti-GD2 immunotherapy induced differentiation in relapsed/refractory high-risk neuroblastoma. Cancers (Basel). 2021; 13(6).
- Morales E, Olson M, Iglesias F, et al. Role of immunotherapy in Ewing sarcoma. J Immunother Cancer. 2020; 8(2).
- Ceppi F, Rivers J, Annesley C, et al. Lymphocyte apheresis for chimeric antigen receptor T-cell manufacturing in children and young adults with leukemia and neuroblastoma. Transfusion. 2018; 58(6): 1414–1420.
- Passweg JR, Baldomero H, Chabannon C, et al. European Society for Blood and Marrow Transplantation (EBMT). The EBMT activity survey on hematopoietic-cell transplantation and cellular therapy 2018: CAR-T's come into focus. Bone Marrow Transplant. 2020; 55(8): 1604–1613.
- Schaft N. The landscape of CAR-T cell clinical trials againstsolid tumors-a comprehensive overview. Cancers (Basel). 2020; 12(9).
